- Intellectual property-based business investor IP Group welcomed news that portfolio company Oxford Nanopore Technologies had been selected as a sequencing partner for a genome project launched by Abu Dhabi's government.

The project would provide citizens with their own high-quality genome as a baseline and incorporate genomic data into healthcare management.

'We're delighted to see Oxford Nanopore selected for a project of this scale which is further impressive validation of nanopore sequencing,' IP Group chief executive Alan Aubrey said.

'This is a significant milestone for Oxford Nanopore and a great example of groundbreaking British innovation that is being adopted around the world.'

IP Group holds an undiluted beneficial stake of 18.1% in Oxford Nanopore, valued at £274.1m.

At 1:43pm: [LON:IPO] IP Group PLC share price was -1.55p at 60.35p

Story provided by